Opioid Induced Constipation Treatment Market Size
The Global Opioid Induced Constipation Treatment Market reached US$ 1,241.90 million in 2025 and is expected to reach US$ 1,835.00 million by 2033, growing at a CAGR of 5.0% during the forecast period 2026-2033.
Opioids are effective for treating and managing pain, but using them frequently can lead to constipation. This can affect comfort, health, and quality of life. According to an article in the BMJ, among people who use opioids for pain relief, constipation affects 52 % of those with advanced cancer and 87% of those with a terminal illness.
Opioid Induced Constipation Treatment Market Strategic Insights
| Metrics | Details |
| Market CAGR | 5.0% |
| Segments Covered | By Distribution Channel, By Route of Administration, By Drug Class, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request free Sample
Opioid Induced Constipation Treatment Market Dynamics
The major driving forces used constipation, recent drug approvals and robust pipeline, and rising opioids for chronic pain.
The rising prevalence of opioid-induced constipation is expected to drive market growth.
The rising prevalence of opioid-induced constipation is expected to boost the market. For instance, in a study carried out in Spain with 317 ambulatory patients undergoing treatment with different opioids for chronic pain, whether caused by cancer or not, 94.6% of patients reported at least one symptom of Opioid-induced bowel dysfunction and constipation. The most frequent symptom was constipation (91.6%). Although opioids are highly efficacious for treating acute and chronic pain, they can also cause several significant side effects. One of the most commonly reported side effects of opioid use is opioid-induced constipation. According to the National Institute of Health, 40–80% who were prescribed opioid drugs experienced constipation due to drug consumption. Thus, the increasing prevalence of opioid-induced constipation is driving the market.
The low diagnosis rate and stiff competition from standard laxatives are restraining the market's growth.
The low diagnosis rate is likely to hamper the market. For instance, clinicians lack awareness about opioid-induced constipation in patients on opioid therapy in Spain, one of the major factors hampering the growth of the opioid-induced constipation market. Even if the clinicians are aware, they do not ask patients about constipation. Usually, patients might feel ashamed to disclose their constipation-related symptoms to clinicians. The major restraint hampering the market's growth is the absence of universal diagnostic criteria for opioid-induced constipation.
Industry analysis.
The Spain opioid-induced constipation market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, and pipeline analysis.
Opioid Induced Constipation Treatment Market Segment Analysis
The antibiotics segment is expected to dominate the Spain opioid-induced constipation market throughout the forecast period (2022-2029).
The Mu-Opioid Receptor Antagonists are expected to grow rapidly over the forecast period (2022-2029). Mu-Opioid Receptor Antagonists (including PAMORAs) are designed to antagonize the intestinal activity of opioids while preserving their systemic effect. Some Mu-Opioid Receptor Antagonist drugs include Naldemedine, Naloxegol, and Methylnaltrexone. The increasing cases of cancer and chronic pain disorders such as arthritis fuel the Mu-Opioid Receptor Antagonists segment growth as these drugs can be used for OIC treatment in patients with chronic pain related to cancer and non-cancer pain. For instance, according to World Cancer Research Funds International, in 2020, there were around 260,455 new cancer cases and 112,335 deaths due to cancer. Thus, the Mu-Opioid Receptor Antagonists are estimated to dominate the Spain Opioid-Induced Constipation market throughout the forecast period.
Opioid Induced Constipation Treatment Market Key Players
The major players operating in the Spain opioid-induced constipation market are AstraZeneca, Shionogi & Company, Limited, Takeda Pharmaceuticals Company Ltd, and Bausch Health Companies Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Spain opioid-induced constipation market. For instance, on 11 August 2022, AstraZeneca acquired TeneoTwo, Inc. Also, on January 10, 2022, Takeda Pharmaceuticals Company Ltd announced its plan to acquire Adaptate Biotherapeutics.
Opioid Induced Constipation Treatment Recent Key Developments
- May 2026 – Shionogi expands naldemedine access in China
Shionogi announced that its group company received National Medical Products Administration (NMPA) approval in China for naldemedine tosylate, a peripherally acting μ-opioid receptor antagonist for opioid-induced constipation (OIC). The product will be marketed in China through Chia Tai Tianqing Pharmaceutical Group, expanding access to targeted OIC treatment in a major pain and oncology market. - March 2026 – New evidence supports naldemedine and magnesium oxide combination therapy
A study published in Supportive Care in Cancer evaluated 171 cancer patients receiving opioid therapy and found that naldemedine was associated with improved bowel movements, including when used with magnesium oxide at doses up to 1,500 mg/day. The findings support continued investigation of combination approaches for patients whose OIC is inadequately controlled with conventional laxatives. - March 2026 – Grünenthal strengthens its established medicines portfolio
Grünenthal acquired Kyowa Kirin International’s 49% stake in Grünenthal Meds, taking full ownership of the joint venture and its portfolio of 12 established brands across six therapeutic areas and more than 60 markets. The transaction builds on Grünenthal’s broader pain-management portfolio, including Movantik (naloxegol) for OIC. - 2026 – Movantik portfolio integration supports OIC treatment expansion
Grünenthal continued integrating and developing its U.S. established-medicines portfolio following its acquisition of Valinor Pharma and Movantik (naloxegol). The company has identified Movantik growth as part of its expansion in the U.S. pain-management market, reinforcing competition among PAMORA-based OIC therapies. - May 2026 – Clinical research advances naldemedine-based OIC management in cancer care
A multicenter randomized controlled trial in Japan began enrolling cancer patients to compare naldemedine with magnesium oxide for opioid-induced constipation and opioid-induced nausea/vomiting. The study is evaluating bowel-movement quality of life, constipation outcomes, nausea/vomiting control, rescue medication use, and other patient-reported outcomes. - April 2026 – Research expands investigation of alternative OIC therapies
A randomized multicenter clinical study in China was registered to evaluate Shouhui Tongbian Capsule versus lactulose for OIC in cancer patients. The trial is examining defecation frequency, stool consistency, symptoms, quality of life, safety, and potential intestinal-flora mechanisms, reflecting continued diversification of the OIC treatment pipeline. - 2026 – OIC treatment strategies increasingly focus on targeted therapies
Market and clinical activity continues to emphasize peripherally acting μ-opioid receptor antagonists (PAMORAs) such as naldemedine, naloxegol, and methylnaltrexone, alongside conventional laxatives. Current market analysis identifies targeted OIC treatment and greater adoption of PAMORA-based therapies as important areas of development.
Takeda Pharmaceutical Company Limited.
Overview:
Takeda Pharmaceutical Company Limited is a multinational pharmaceutical company with partial American and British roots. It is one of Asia's largest pharmaceutical top 20 companies and was founded in 1781 by Chobei Takeda.
Product Portfolio:
Takeda Pharmaceutical Company Limited’s product portfolio for opioid-induced constipation treatment has AMITIZA (lubiprostone).
The opioid-induced constipation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages
